IP Library Granted Patent US 9,226,952
Granted Patent B2
US 9,226,952 · App. 14/195,401 · Granted Jan 5, 2016

Na/K-ATPase-derived peptide Src inhibitors and ouabain antagonists and uses thereof

Inventors: Zi-Jian Xie (Saline, MI); Zhichuan Li (Toledo, OH); Joseph I. Shapiro (Toledo, OH)
Assignee: The University of Toledo
A61K38/46C07K14/4703C12N9/14A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,226,952
App. No.
14/195,401
Granted
Jan 5, 2016
Kind
B2
Abstract

A novel Src inhibitor that targets the Na/K-ATPase/Src receptor complex and antagonizes ouabain-induced protein kinase cascades and uses thereof are disclosed.

Claims (7)

1. A composition of matter comprising an isolated amino acid peptide consisting of the sequence KKGKKGKKSATWLALSRIAGLCNRAVFQ [SEQ ID NO:9].

2. The composition of claim 1 , further comprising a therapeutically acceptable excipient.

3. The composition of claim 1 , wherein the peptide is capable of Src inhibition.

4. The composition of claim 1 , which further comprises at least one additional therapeutic composition useful to treat a disease selected from the group consisting of: cancer; vascular disease; cardiovascular disease; heart disease; bone disease; prostate cancer; breast cancer; neuroblastoma; cardiac hypertrophy; tissue fibrosis; congestive heart failure; ischemia/reperfusion injury; and osteoporosis.

5. The composition of claim 1 , further comprising at least one additional therapeutic composition to treat cancer.

6. The composition of claim 1 , wherein the peptide is capable of a cellular process selected from the group consisting of: antagonizing a CTS-induced protein kinase cascade; Src inhibition; Na/K-ATPase mimic; Lyn inhibition; ouabain antagonism; FAK/ERK1/2 inhibition; anti-angiogenesis; and inhibition of cell growth.

7. The composition of claim 1 , further comprising a second compound bound with the amino acid sequence, wherein the second compound is selected from the group consisting of: chemotherapeutic drug; toxin; immunological response modifier; enzyme; and radioisotope.

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 20, 2015
From: UNIVERSITY OF TOLEDO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035451/0335 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2014
From: XIE, ZI-JIAN; LI, ZHICHUAN; SHAPIRO, JOSEPH I.
To: THE UNIVERSITY OF TOLEDO
Reel/Frame 032342/0285 →
Continuity (3)
Division 13133252
Provisional Application 61122205 · Dec 12, 2008
Related Publication 20140187484A1 · Jul 3, 2014